Skip to main content
Clinical Trials/NCT05439811
NCT05439811Not yet recruitingNot Applicable

Retrospective Data Analysis on the Application of Swan-Ganz Catheter in Cardiac Surgery

Huazhong University of Science and Technology0 sites3,000 target enrollmentStarted: June 30, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
3,000
Primary Endpoint
Number of participants respiratory adverse events

Study Overview

Brief Summary

The investigators aimed to investigate postoperative complications associated with Swan-Ganz Catheter based on the clinical data of Wuhan Union Hospital and Wuhan Asian heart hospital for 10 years, including major cardiovascular, respiratory adverse events, ICU time, mechanical ventilation time, length of hospital stay, in-hospital mortality, and 30-day postoperative mortality events.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Over 18 years old;
  • •Patients undergoing major cardiac surgery under general anesthesia;
  • •Patients with complete sex, age, use of floating catheter and prognosis data

Exclusion Criteria

  • •ASA grade V and above;
  • •End stage renal disease requiring (or undergoing) renal replacement therapy;
  • •Pregnant or lactating women

Outcomes

Primary Outcomes

Number of participants respiratory adverse events

Time Frame: one week after operation

1) Acute lung injury: Diagnosis according to Berlin diagnostic standard; 2) Atelectasis: X-ray confirmed with body temperature \>37.5c or abnormal pulmonary manifestations; 3) Pneumothorax: chest X-ray diagnosis; 4) Pneumonia: confirmed by radiology or bacteriology

Number of participants with cardiovascular events

Time Frame: one week after operation

1) Cardiac death; 2) Non fatal myocardial infarction; 3) Intra aortic balloon counterpulsation (IABP); 4) Thoracotomy exploration; 5) Heart failure.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Shanglong Yao

Clinical Professor

Wuhan Union Hospital, China

Similar Trials